Dr. Lapuerta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 Seminole Rd
Skillman, NJ 08558Phone+1 609-216-3513
Education & Training
Harvard Medical SchoolClass of 1989
Certifications & Licensure
CA State Medical License 1992 - Present
NJ State Medical License 1996 - 2025
NC State Medical License 1989 - 1991
Clinical Trials
- Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) Start of enrollment: 2007 Dec 01
- Pharmacodynamics of CGT 2168 Compared With Plavix® Start of enrollment: 2007 Nov 01
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Start of enrollment: 2010 Jun 15
Publications & Presentations
PubMed
- 2 citationsTelotristat ethyl reverses myxomatous changes in mice mitral valves.Xinmei Wang, Danielle Kuban-Johnston, Pablo Lapuerta, Carla M R Lacerda
Frontiers in Cardiovascular Medicine. 2022-01-01 - 988 citationsSotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L. Bhatt, Michael Szarek, P. Gabriel Steg, Christopher P. Cannon, Lawrence A. Leiter
The New England Journal of Medicine. 2021-01-14 - 597 citationsSotagliflozin in Patients with Diabetes and Chronic Kidney Disease.Deepak L. Bhatt, Michael Szarek, Bertram Pitt, Christopher P. Cannon, Lawrence A. Leiter
The New England Journal of Medicine. 2021-01-14
Journal Articles
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine
Press Mentions
Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes CareJune 25th, 2018- Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes CareJune 23rd, 2018
Sotagliflozin (Zynquista): A Novel SGLT MedicationJune 16th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
